logologo
QuantliQuantli

Neurogene Inc

NGNE

NASDAQ

Biotechnology

$36.14

USD

+0.51 (+1.43%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $719.91M

Volume 115.9K

Price (USD)
Price (USD)

About Neurogene Inc

The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2014-03-07.

CEO

Dr. Rachel Mcminn

HQ

New York City, NEW YORK, US

Founded

2014

Employees

131

Key Metrics

2 metrics our research team weighs before forming a view on NGNE.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

ROE (TTM)

-51.2%

-20.3 pp

Free Cash Flow (TTM)

$-87.71M

Financial Snapshot

Full Financials

Revenue

$0

YoY

Gross Margin

YoY

Net Income

$-111.11M

-31.7%

YoY

Operating Cash Flow

$-86.82M

-18.4%

YoY

Key Statistics

Open

$35.44

Previous Close

$35.63

Day Range

$34.47 - $36.40

52 Week Range

$15.93 - $43.66

Volume

115.9K

Average Volume (10 Days)

190.0K

Dividend Yield

Valuation Measurement

Market Cap

$719.91M

P/E Ratio (TTM)

Price / Book

3.32

Financial Highlights

Return on Assets

-45.5%

Return on Equity

-51.2%

Revenue (TTM)

$0

Net Income (TTM)

$-111.11M

Diluted EPS (TTM)

-$5.03

Total Cash (MRQ)

$112.48M

Levered FCF (TTM)

$-87.71M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Go deeper on NGNE

Similar Stocks

GYRE

Gyre Therapeutics Inc

$6.68

+2.1%

MNPR

Monopar Therapeutics Inc

$113.04

+2.4%

BBOT

BridgeBio Oncology Therapeutics Inc

$9.06

-1.8%

CTMX

CytomX Therapeutics Inc

$3.36

+0.3%

RGNX

Regenxbio Inc

$10.77

+1.0%

ALLO

Allogene Therapeutics Inc

$2.05

+3.5%

TECX

Tectonic Therapeutic Inc

$34.91

+2.7%

IRWD

Ironwood Pharmaceuticals Inc

$4.31

+5.6%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 11

Est. EPS

Adjusted consensus estimate

-$1.37

Analyst Consensus

Buy

Based on 2 analyst ratings

Avg Target: $73.00

(+102.0% upside)

High: $81.00 · Low: $65.00

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

View full analyst ratings